Picture of Viatris logo

VTRS — Viatris News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapNeutral

Viatris Q3 adjusted EPS beats estimates; hikes forecast

Viatris Q3 adjusted EPS beats estimates; hikes forecast


Overview

  • Healthcare company's Q3 revenue was flat yr/yr and missed analyst expectations

  • Adjusted EPS for Q3 rose 6% and beat analyst expectations

  • Company raised 2026 financial guidance midpoints for all key metrics


Outlook

  • Viatris raises 2026 total revenue guidance midpoint to $14.8 bln from $14.75 bln

  • Company lifts 2026 adjusted EBITDA guidance midpoint to $4.5 bln from $4.4 bln

  • Viatris increases 2026 adjusted EPS guidance midpoint to $2.60 from $2.52


Result Drivers

  • SUPPLY CONSTRAINTS AND COMPETITION - Co said supply constraints in Europe and Emerging Markets and increased competition offset growth from new products and Greater China

  • NEW PRODUCT SALES - Co said new product sales contributed to revenue, primarily in Developed Markets

  • GREATER CHINA BRANDS - Co said continued strength in Greater China brands supported revenue


Company press release: ID:nPn8s3C4ba


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$3.75 bln

$3.79 bln (8 Analysts)

Q3 Adjusted EPS

Beat

$0.71

$0.64 (9 Analysts)

Q3 Loss Per Share

$0.28

Q3 Net Loss

$325.30 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Viatris Inc. is $20.00, about 4.1% above its November 4 closing price of $19.22

  • The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago


Reuters Recommended Reads

  • Nov 3 - Henry Schein Q3 sales slightly miss, raises 2026 profit outlook

  • Nov 4 - Perrigo Q3 sales slightly beat expectations on market share gains

  • Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Viatris

See all news